Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

573 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma.
Yoshino M, Ishihara H, Nemoto Y, Mizoguchi S, Ikeda T, Nakayama T, Fukuda H, Yoshida K, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Yoshino M, et al. Among authors: nemoto y. Target Oncol. 2024 Jul;19(4):623-633. doi: 10.1007/s11523-024-01069-6. Epub 2024 May 31. Target Oncol. 2024. PMID: 38819770
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: nemoto y. Target Oncol. 2023 Jan;18(1):159-168. doi: 10.1007/s11523-022-00940-8. Epub 2022 Dec 26. Target Oncol. 2023. PMID: 36571708
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: nemoto y. Target Oncol. 2023 Mar;18(2):209-220. doi: 10.1007/s11523-023-00956-8. Epub 2023 Mar 21. Target Oncol. 2023. PMID: 36941516
Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Nakamura K, Ishiyama Y, Nemoto Y, Ishihara H, Tachibana H, Fukuda H, Shinmura H, Hashimoto Y, Yoshida K, Iizuka J, Ishida H, Kondo T, Takagi T. Nakamura K, et al. Among authors: nemoto y. Int J Clin Oncol. 2023 Jul;28(7):913-921. doi: 10.1007/s10147-023-02341-x. Epub 2023 Apr 27. Int J Clin Oncol. 2023. PMID: 37103730
Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma.
Ishihara H, Nemoto Y, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: nemoto y. Clin Genitourin Cancer. 2024 Apr;22(2):549-557.e5. doi: 10.1016/j.clgc.2024.01.010. Epub 2024 Jan 15. Clin Genitourin Cancer. 2024. PMID: 38281878
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H, Omae K, Nemoto Y, Ishiyama R, Tachibana H, Nishimura K, Ikeda T, Kobari Y, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Among authors: nemoto y. Int J Clin Oncol. 2024 Apr;29(4):473-480. doi: 10.1007/s10147-024-02471-w. Epub 2024 Feb 12. Int J Clin Oncol. 2024. PMID: 38345708
Prognostic Impact of the Administration of Antibiotics and Proton Pump Inhibitors in Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma.
Katsurayama N, Ishihara H, Ishiyama R, Nemoto Y, Ikeda T, Mizoguchi S, Nakayama T, Fukuda H, Yoshida K, Iizuka J, Shinmura H, Hashimoto Y, Kondo T, Takagi T. Katsurayama N, et al. Among authors: nemoto y. Cancer Diagn Progn. 2024 Jul 3;4(4):496-502. doi: 10.21873/cdp.10354. eCollection 2024 Jul-Aug. Cancer Diagn Progn. 2024. PMID: 38962540 Free PMC article.
Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era.
Ishihara H, Nemoto Y, Mizoguchi S, Nishimura K, Ikeda T, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Among authors: nemoto y. Int J Clin Oncol. 2024 Nov;29(11):1730-1739. doi: 10.1007/s10147-024-02606-z. Epub 2024 Aug 14. Int J Clin Oncol. 2024. PMID: 39143429
573 results